• By ICR Secretariat
  • Posted Thursday, August 18, 2022

NICE recommendation expands patient eligibility for AbbVie’s Ozurdex

https://www.pharmatimes.com/news/nice_recommendation_expands_patient_eligibility_for_abbvies_ozurdex_1453278

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending the dexamethasone intravitreal implant – also known as Ozurdex – as a treatment option within the NHS, for adults with visual impairment caused by diabetic macular oedema (DMO).